Theranostics: Evolution of the radiopharmaceutical meta-iodobenzylguanidine in endocrine tumors

Seminars in Nuclear Medicine

Volumn 42, Issue 3, 2012, Pages 171-184

  Sisson, James C ^a   Yanik, Gregory A ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 5 HYDROXYINDOLEACETIC ACID; ADRENALIN; ANTIEMETIC AGENT; CALCITONIN; CARBOPLATIN; CHROMOGRANIN A; CISPLATIN; CORTICOTROPIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IRINOTECAN; MELPHALAN; NORADRENALIN; PENTETREOTIDE IN 111; POTASSIUM IODIDE; POTASSIUM PERCHLORATE; SEROTONIN; TOPOTECAN; ULTRATRACE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOID; CLINICAL EVALUATION; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; CUSHING SYNDROME; DRUG APPROVAL; FEASIBILITY STUDY; GASTROINTESTINAL DISEASE; HEALTH CARE COST; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HORMONE RELEASE; HUMAN; HYPERTENSION; HYPOGONADISM; HYPOTHYROIDISM; ISCHEMIC HEART DISEASE; ISOTOPE LABELING; KIDNEY DISEASE; LIVER VENOOCCLUSIVE DISEASE; LUNG DISEASE; LYMPHOCYTOPENIA; MALIGNANT NEURILEMOMA; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUROBLASTOMA; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PAROTITIS; PATIENT CARE; PERITONEUM MESOTHELIOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHEOCHROMOCYTOMA; RADIATION DOSE; RADIATION SAFETY; RADIOSENSITIVITY; SENSITIVITY AND SPECIFICITY; TACHYCARDIA; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE; TUMOR SCINTISCANNING; TUMOR VOLUME; VOMITING;

EID: 84859306773     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2011.11.004     Document Type: Review

References (151)

1. D.M. Wieland, J. Wu, L.E. Brown Radiolabeled adrenergic neuron-blocking agents: Adrenomedullary imaging with [131I]iodobenzylguanidine J Nucl Med 21 1980 349 353
2. D.M. Wieland, L.E. Brown, M.C. Tobes Imaging the primate adrenal medulla with [123I]meta-iodobenzyguanidine: Concise communication J Nucl Med 22 1981 359 364
3. J.C. Sisson, M.S. Frager, T.W. Valk Scintigraphic localization of pheochromocytoma N Engl J Med 305 1981 12 17
4. B. Kimmig, W.E. Brandeis, M. Eisenhut Scintigraphy of a neuroblastoma with I-131 meta-iodobenzylguanidine J Nucl Med 25 1984 773 775
5. S. Jaques Jr, M.C. Tobes, J.C. Sisson Comparison of the sodium dependency of uptake of meta-iodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells Mol Pharmocol 26 1984 539 546
6. M.C. Tobes, S. Jaques Jr, D.M. Wieland Effect of uptakeone inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine J Nucl Med 26 1985 897 907
7. B. Gasnier, M.P. Roisin, D. Scherman Uptake of meta-iodobenzylguanidine by bovine chromaffin granule membranes Mol Pharmacol 29 1986 275 280
8. S. Jaques Jr, M.C. Tobes, J.C. Sisson Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: Evidence for uptake-one Cancer Res 47 1987 3920 3928
9. F.A. Khafagi, B. Shapiro, L.M. Fig Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues J Nucl Med 30 1989 481 489
10. B.L. Shulkin, B. Shapiro Current concepts on the diagnostic use of MIBG in children J Nucl Med 39 1998 679 688
11. T.J. Mangner, M.C. Tobes, D.W. Wieland Metabolism of iodine-131 metaiodobenzylguanidine in patients with metastatic pheochromocytoma J Nucl Med 27 1986 37 44
12. A.R. Wafelman, C.A. Hoefnagel, R.A. Maes Radioiodinated metaiodobenzylguanidine: A review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry Eur J Nucl Med 21 1994 545 559
13. M.D. Lynn, F. Shapiro, J.C. Sisson Pheochromoctoma and the normal adrenal medulla: Improved visualization with I-123 MIBG scintigraphy Radiology 156 1985 789 792
14. J. Buck, G. Gruchelt, R. Girgert Specific uptake of m-[125I] iodobenzylguanidine in the human neuroblastoma cell line SK-N-SH Cancer Res 45 1985 6366 6370
15. J. Clerc, S. Halpern, C. Fourré SIMS microscopy imaging of the intratumor biodistribution of metaiodobenzylguanidine in the human SK-N-SH neuroblastoma cell line xenografted into nude mice J Nucl Med 34 1993 1565 1570
16. B. Shapiro, J.E. Copp, J.C. Sisson Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: Experience in 400 cases J Nucl Med 26 1985 576 585
17. B. Shapiro, J.C. Sisson, B.L. Shulkin The current status of meta-iodobenzylguanidine and related agents for the diagnosis of neuro-endocrine tumors Q J Nucl Med 39 Suppl 1 1995 3 8
18. 123 I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: Results from a prospective multicenter trial J Nucl Med 50 2009 1448 1454
19. 123 I-meta- iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: Results of a meta-analysis J Clin Endocrinol Metab 95 2010 2596 2606
20. A.S. Berglund, U.L. Hulthén, P. Manhem Metaiodobenzylguanidine (MIBG) scintigraphy and computed tomography (CT) in clinical practice Primary and secondary evaluation for localization of phaeochromocytomas J Intern Med 249 2001 247 251
21. 123 I-MIBG scintigraphy in localizing pheochromocytomas: A prospective study Nucl Med Commun 27 2006 383 587
22. H.J. Timmers, A. Kozupa, C.C. Chen Superiority of fluordeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma J Clin Oncol 16 2007 2262 2269
23. R. Milardovic, E.P. Corssmit, M. Stokkel Value of 123I-MIBG scintigraphy in paraganglioma Neuroendocrinology 91 2010 94 100
24. 18 F]FDOPA-PET in the localization of exta-adrenal paragangliomas: The case for a patient-tailored use of nucliear imaging modalities Clin Endocrinol 74 2011 21 29
25. 123 I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas J Nucl Med 49 2008 1232 1237
26. B.L. Shulkin, N.W. Thompson, B. Shapiro Pheochromocytomas: Imaging with 2-[fluorine-18]fluoro-2-deoxy-d-glucose PET Radiology 212 1999 35 41
27. 18 F-FDG-PETin the management of malignant and multifocal phaeochromocytomas Clin Endocrinol 69 2008 580 586
28. 18 F-FDG avidity of pheochromocytomas and paragangliomas: A new molecular imaging signature? J Nucl Med 50 2009 711 717
29. 123 I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma J Clin Endocrinol Metab 94 2009 4757 4767
30. 18 F] fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma Hypertension 38 2001 6 8
31. 18 F-fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma J Nucl Med 48 2007 1599 1606
32. P. Kaji, J.A. Carrasquillo, W.M. Linehan The role of 6-[18F] fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von HippelLindau syndrome Eur J Endocrinol 156 2007 483 487
33. 111 In-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma J Nucl Med 49 2008 1613 1619
34. 18 F-FDOPA PET and PET/CT accurately localize pheochromocytomas J Nucl Med 50 2009 513 519
35. 123 I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess J Clin Endocrinol Metab 94 2009 3922 3930
36. C. Fottner, A. Helisch, M. Anlauf 6-18F-fluoro-L-dihydroxyphenylanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochomocytomas and paragangliomas: Correlation with vesicular monoamine transporter expression J Clin Endocrinol Metab 95 2010 2800 2810
37. 111 In-pentetreotide scintigraphy J Clin Endocrinol Metab 96 2011 2779 2785
38. J. Miskulin, B.L. Shulkin, G.M. Doherty Is preoperative iodine 123 meta-iodobenzylguanidine scintigraphy routinely necessary before initial adrenalectomy for pheochromocytoma? Surgery 134 2003 918 923
39. D.Y. Greenblatt, Y. Shenker, H. Chen The utility of metaiodobenzylguanidine (MIBG) scintigraphy in patients with pheochromocytoma Ann Surg Oncol 15 2008 900 905
40. 123 I- metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation Clin Endocrinol 69 2008 181 188
41. 18 F]-fluorodopamine emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO) Clin Endocrinol 71 2009 11 17
42. B. Havekes, K. King, E.W. Lait New imaging approaches to phaeochromocytomas and paragangliomas Clin Endocrinol 72 2010 137 145
43. G. Eisenhofer, H.J. Timmers, J.W. Lenders Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location J Clin Endocrinol Metab 96 2011 375 384
44. L. Amar, J. Bertherat, E. Baudin Genetic testing in pheochromocytoma or functional paraganglioma J Clin Oncol 23 2005 8812 8818
45. M. Mannelli, M. Castellano, F. Schiavi Clinically guided genetic screening in a large cohort of Italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas J Clin Endocrinol Metab 94 2009 1541 1547
46. J.M. Friedman, P.H. Birch Type1 neurofibromatosis: A descriptive analysis of the disorder in 1728 patients Am J Med Genet 70 1997 138 143
47. F.M. Brouwers, G. Eisenhofer, J.J. Tao High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: Implications for genetic testing J Clin Endocrinol Metab 91 2006 4505 4509
48. J.V. Glowniak, B. Shapiro, J.C. Sisson Familial extra-adrenal pheochromocytoma A new syndrome Arch Intern Med 145 1985 257 261
49. O. Navalkele, M.S. Dorisio, T.M. O Dorisio Incidence, survival and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: Nine standard SEER registries, 1975-2006 Pediatr Blood Cancer 56 2011 50 57
50. K.K. Matthay, J.G. Villablanca, R.C. Seeger et al. Children's Cancer Group: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoid acid N Engl J Med 341 1999 1165 1173
51. A. Suc, J. Lumbroso, H. Rubie Metastatic neuroblastoma in children older than one year: Prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system Cancer 77 1996 805 811
52. M.J. Gelfand, M.T. Parisi, S.T. Treves Pediatric radiopharmaceutical administered doses: 2010 North Amercan consensus guidelines J Nucl Med 52 2011 318 322
53. V. Rufini, G.A. Fisher, B.L. Shulkin Iodine-123-MIBG imaging of neuroblastoma: Utility of SPECT and delayed imaging J Nucl Med 37 1996 1464 1468
54. A. Leung, B. Shapiro, R. Hattner Specificity of radioiodinated MIBG, for neural crest tumors of childhood J Nucl Med 38 1997 1352 1357
55. I. Gordon, A.M. Peters, A. Gutman Skeletal assessment in neuroblastomaThe pitfalls of iodine-123-MIBG scans J Nucl Med 31 1990 129 134
56. B.L. Shulkin, B. Shapiro, R.J. Hutchinson Iodine-131- metaiodobenzylguanidine and bone scinitigraphy for detection of neuroblastoma J Nucl Med 33 1992 1735 1740
57. T. Pfluger, C. Schmied, U. Porn Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma AJR Am J Roentgenol 181 2003 1115 1124
58. B.H. Kushner Neuroblastoma: A disease requiring a multitude of imaging studies J Nucl Med 45 2004 1172 1188
59. B.L. Shulkin, R.J. Hutchinson, V.P. Castle Neuroblastoma: Positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy Radiology 199 1996 743 750
60. 123 I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: Diagnostic comparison and survival analysis J Nucl Med 52 2011 519 525
61. 18 F-FDG PET in neuroblastoma J Nucl Med 50 2009 1237 1243
62. M.U. Khan, M. Morse, R.E. Coleman Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors Q J Nucl Med Mol Imaging 52 2008 441 454
63. I.M. Modlin, K.D. Lye, M. Kidd A 5-decade analysis of 13,715 carcinoid tumors Cancer 97 2003 934 959
64. I.M. Modlin, M. Kidd, I. Latich Current status of gastrointestinal carcinoids Gastroenterology 128 2005 1717 1781
65. P.K. Woodard, J.M. Feldman, S.S. Paine Midgut carcinoid tumors: CT findings and biochemical profiles J Comput Assist Tomogr 19 1995 400 405
66. I.M. Modlin, I. Latich, M. Zikusoka Gastrointestinal carcinoids: The evolution of diagnostic strategies J Clin Gastroenterol 40 2006 572 582
67. J.M. Feldman, R.A. Blinder, K.J. Lucas Iodine-131 metaiodobenzylguanidine scintigraphy of carcinoid tumors J Nucl Med 27 1986 1691 1696
68. 131 I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease Nucl Med Commun 23 2002 735 741
69. M.W. Hanson, J.M. Feldman, R.A. Blinder Carcinoid tumors: Iodine-131 MIBG scintigraphy Radiology 172 1989 699 703
70. G. Kaltsas, M. Korbonits, E. Heintz Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advance neuroendocrine tumors J Clin Endocrinol Metab 86 2001 895 902
71. C. Le Rest, J.B. Bomanji, D.C. Costa Functional imaging of malignant paragangliomas and carcinoid tumours Eur J Nucl Med 28 2001 478 482
72. 131 I-meta-iodobenzylguanidine (131I-mIBG) Clin Endocrinol 55 2001 47 60
73. M.R. Castellani, E. Seregni, M. Maccauro MIBG for diagnosis and therapy of medullary thyroid carcinoma: Is there still a role? Q J Nucl Med Mol Imaging 52 2008 430 440
74. S. Roman, R. Lin, J.A. Sosa Prognosis of medullary thyroid carcinoma Demographic, clinical, and pathologic predictors of survival in 1252 cases Cancer 107 2006 2134 2142
75. A.L. Giraudet, D. Vanel, S. Leboulleux Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels J Clin Endocrinol Metab 92 2007 4185 4190
76. 18 F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels J Nucl Med 48 2007 501 507
77. A. Faggiano, F. Grimaldi, L. Pezzullo Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer Endocr Relat Cancer 16 2009 225 231
78. L. Gourgiotis, N.J. Sarlis, J.C. Reynolds Localization of medullary thyroid carcinoma metastasis in a multiple endocrine neoplasia type 2A patient by 6-[18F]-fluorodopamine positron emission tomography J Clin Endocrinol Metab 88 2003 637 641
79. 123 I-MIBG as predictors for radionuclide therapy J Cancer Res Clin Oncol 130 2004 649 656
80. J.C. Sisson, B. Shapiro, W.H. Beierwaltes Radiopharmaceutical treatment of malignant pheochromocytoma J Nucl Med 24 1984 197 206
81. J.C. Sisson, B. Shapiro, B.L. Shulkin Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy Am J Clin Oncol 22 1999 364 370
82. E. Forssell-Aronsson, P. Bernhardt, B. Wngberg Aspects on radionuclide therapy in malignant pheochromocytomas Ann N Y Acad Sci 1073 2006 498 504
83. A. Chrisoulidou, G. Kaltsas, I. Ilias The diagnosis and management of malignant phaeochromocytoma and paraganglioma Endocr Relat Cancer 14 2007 569 585
84. E.J. Postema, A.J. McEwan Radioiodinated metaiodobenzylguanidine treatment of neuroendocrine tumors in adults Cancer Biother Radiopharm 24 2009 519 524
85. M.G. Lam, C.J. Lips, P.L. Jager Repeated [131I]metaiodobenzylguanidine therapy in two patients with malignant pheochromocytoma J Clin Endocrinol Metab 90 2005 5888 5895
86. G.K. Gedik, C.A. Hoefnagel, E. Bais 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma Eur J Nucl Med Mol Imaging 35 2008 725 733
87. S. Gonias, R. Goldsby, K.K. Matthay Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma J Clin Oncol 27 2009 4162 4168
88. J.C. Sisson, B.L. Shulkin, N.H. Esfandiari Courses of malignant pheochromocytoma: Implications for therapy Ann N Y Acad Sci 1073 2006 505 511
89. R. Ladenstein, T. Philip, C. Lasset Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: A report from the European bone marrow transplantation solid tumor registry J Clin Oncol 16 1998 953 965
90. M.L. Schmidt, A. Lal, R.C. Seeger Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: A Children's Cancer Group study J Clin Oncol 23 2005 6474 6480
91. W.B. London, R.P. Castleberry, K.K. Matthay Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the children's Oncology Group J Clin Oncol 23 2005 6459 6465
92. J.D. Lumbroso, F. Guermazi, O. Hartmann Meta-iodobenzylguanidine (MIBG) scans in neuroblastoma: Sensitivity and specificity, a review of 115 scans Prog Clin Biol Res 271 1988 689 705
93. F. Claudiani, P. Stimamiglio, L. Bertolazzi Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma Q J Nucl Med 39 1995 21 24
94. P.G. Montaldo, M. Lanciotti, A. Casalaro Accumulation of m-iodobenzylguanidine by neuroblastoma cells results from independent uptake and storage mechanisms Cancer Res 51 1991 4342 4346
95. L.A. Smets, C. Loesberg, M. Janssen Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells Cancer Res 49 1989 2941 2944
96. M.N. Gaze, I.M. Huxham, R.J. Mairs Intracellular localization of metaiodobenzyl-guanidine in human neuroblastoma cells by electron spectroscopic imaging Int J Cancer 47 1991 875 880
97. L.S. Lashford, J.P. Hancock, J.T. Kemshead Meta-iodobenzylguanidine (MIBG) uptake and storage in the human neuroblastoma cell line SK-N-BE(2C) Int J Cancer 47 1991 105 109
98. S. Carlin, R.J. Mairs, A.G. McCluskey Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors Clin Cancer Res 9 2003 3338 3344
99. A. Armour, S.H. Cunningham, M.N. Gaze The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro Br J Cancer 75 1997 470 476
100. D. Meco, A. Lasorella, A. Riccardi Influence of cisplatin and doxorubicin on 125I-meta-iodobenzylguanidine uptake in human neuroblastoma cell lines Eur J Cancer 35 1999 1227 1234
101. A.G. McCluskey, M. Boyd, S.C. Ross [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter Clin Cancer Res 11 2005 7929 7937
102. R.J. Hutchinson, J.C. Sisson, J.S. Miser Long-term results of [131I]metaiodobenzylguanidine treatment of refractory advanced neuroblastoma J Nucl Biol Med 35 1991 237 240
103. R.J. Hutchinson, J.C. Sisson, B. Shapiro 131-I-metaiodobenzylguanidine treatment in patients with refractory advanced neuroblastoma Am J Clin Oncol 15 1992 226 232
104. L.S. Lashford, I.J. Lewis, S.L. Fielding Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: A United Kingdom children's Cancer Study Group investigation J Clin Oncol 10 1992 1889 1896
105. K.K. Matthay, J.P. Huberty, R.S. Hattner Efficacy and safety of [131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma J Nucl Biol Med 35 1991 244 247
106. T. Klingebiel, U. Feine, J. Treuner Treatment of neuroblastoma with [131I]metaiodobenzylguanidine: Long-term results in 25 patients J Nucl Biol Med 35 1991 216 219
107. L. Troncone, V. Rufini, R. Riccardi The use of [131I] metaiodobenzylguanidine in the treatment of neuroblastoma after conventional therapy J Nucl Biol Med 35 1991 232 236
108. T.I. Kang, P. Brophy, M. Hickeson Targeted radiotherapy with submyeloablative doses of 131IMIBG is effective for disease palliation in highly refractory neuroblastoma J Pediatr Hematol/Oncol 25 2003 769 773
109. F. Claudiani, A. Garaventa, L. Bertolazzi [131I]metaiodobenzylguanidine therapy in advanced neuroblastoma J Nucl Biol Med 35 1991 224 227
110. A. Garaventa, O. Bellagamba, M.S. Lo Piccolo 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: A mono-institutional experience with 43 patients Br J Cancer 81 1999 1378 1384
111. K.K. Matthay, K. DeSantes, B. Hasegawa Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma J Clin Oncol 16 1998 229 236
112. C.A. Hoefnagel, P.A. Vote, J. De Kraker [131I] metaiodobenzylguanidine therapy after conventional therapy for neuroblastoma J Nucl Biol Med 35 1991 202 206
113. J. Lumbroso, O. Hartmann, M. Schlumberger Therapeutic use of [131I]metaiodobenzylguanidine in neuroblastoma: A phase II study in 26 patients "Societe Franaise d'oncologie pediatrique" and nuclear medicine co-investigators J Nucl Biol Med 35 1991 220 223
114. K.K. Matthay, G. Yanik, J. Messina Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131- metaiodobenzylguanidine therapy in refractory neuroblastoma J Clin Oncol 25 2007 1054 1060
115. T. Klingebiel, P. Bader, R. Bares Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy A pilot study Eur J Cancer 34 1998 1398 1402
116. G.A. Yanik, J.E. Levine, K.K. Matthay Pilot study of iodine-131- metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma J Clin Oncol 20 2002 2142 2149
117. K.K. Matthay, J.C. Tan, J.G. Villablanca Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A new approaches to neuroblastoma therapy consortium study J Clin Oncol 24 2006 500 506
118. S.G. Dubois, L. Chesler, S. Groshen Phase I study of vincristine, irinotecan, and 131I-MIBG for patients with refractory neuroblastoma: A New Approaches to Neuroblastoma Therapy consortium study Advances in Neuroblastoma Research (ANR) Conference, Stockholm, Sweden June 2010 202 (abstract POC7)
119. M.N. Gaze, Y.C. Chang, G.D. Flux Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma Cancer Biother Radiopharm 20 2005 195 199
120. R. Mastrangelo, A. Tornesello, R. Riccardi A new approach in the treatment of stage IV neuroblastoma using a combination of [131I]meta- iodobenzylguanidine (MIBG) and cisplatin Eur J Cancer 31A 1995 606 611
121. R. Mastrangelo, A. Tornesello, A. Lasorella Optimal use of the 131-I-metaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma J Neuro Oncol 31 1997 153 158
122. K. Johnson, B. McGlynn, J. Saggio Safety and efficacy of tandem (131) I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma Pediatr Blood Cancer 57 2011 1124 1129
123. J.P. Howard, J.M. Maris, L.S. Kersun Tumor response and toxicity with multiple infusions of high dose (131)I-MIBG for refractory neuroblastoma Pediatr Blood Cancer 44 2005 232 239
124. K.K. Matthay, A. Quach, J. Huberty Iodine-131Metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: A new approaches to neuroblastoma therapy phase I study J Clin Oncol 27 2009 1020 1025
125. S. Mastrangelo, V. Rufini, A. Ruggiero Treatment of advanced neuroblastoma in children over 1 year of age: The critical role of 131I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen Pediatr Blood Cancer 56 2011 1032 1040
126. J. de Kraker, K.A. Hoefnagel, A.C. Verschuur Iodine-131- metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age Eur J Cancer 44 2008 551 556
127. M. Schmidt, T. Simon, B. Hero Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of the German neuroblastoma trial NB97 and implications for the German neuroblastoma trial NB2004 Nuklearmedizin 45 2006 145 151
128. N. Ady, J.M. Zucker, B. Asselain A new 123I-MIBG whole body scan scoring methodApplication to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma Eur J Cancer 31A 1995 256 261
129. K.K. Matthay, V. Edeline, J. Lumbroso Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma J Clin Oncol 21 2003 2486 2491
130. J.A. Messina, S.C. Cheng, B.L. Franc Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (MIBG) scans in patients with relapsed neuroblastoma Pediatr Blood Cancer 47 2006 865 874
131. Y. Perel, J. Conway, M. Kletzel Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma J Pediat Hematol Oncol 21 1999 13 18
132. H.M. Katzenstein, S.L. Cohn, R.M. Shore Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma J Clin Oncol 22 2004 3909 3915
133. 131 I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: A report from the children's Oncology Group Pediatr Blood Cancer 56 2011 1041 1045
134. G.A. Yanik, M.T. Parisi, A. Naranjo et al. Children's Oncology Group: Analyses of MIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma (COG A3973) report Advances in Neuroblastoma Research (ANR) Conference, Stockholm, Sweden June 2010 102 (abstract PL30)
135. J.C. Sisson, R.J. Hutchinson, B. Shapiro Iodine-125-MIBG to treat neuroblastoma: Preliminary report J Nucl Med 31 1990 1479 1485
136. J.C. Sisson, B. Shapiro, R.J. Hutchinson Survival of patients with neuroblastoma treated with 125-I MIBG Am J Clin Oncol 19 1996 144 148
137. W. Weber, J. Weber, R. Senekowitsch-Schmidtke Therapuetic effect of m-[131I] and m-[125I] iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes Cancer Res 56 1996 5428 5434
138. J.A. Barrett, J.L. Joyal, S.M. Hillier Comparison of high-specific- activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution Cancer Biother Radiopharm 25 2010 299 308
139. S. Modak, N. Pandit-Taskar, B.H. Kushner Transient sialoadenitis: A complication of (131)I-metaiodobenzylguanidine therapy Pediatr Blood Cancer 50 2008 1271 1273
140. J.C. Sisson, B. Shapiro, R.J. Hutchinson Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine Eur J Nucl Med 21 1994 46 52
141. K.K. Matthay, C. Panina, J. Huberty Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131) I-MIBG J Nucl Med 42 2001 1713 1721
142. S.G. Dubois, J. Messina, J.M. Maris Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma J Clin Oncol 22 2004 2452 2460
143. P. Picco, A. Garaventa, F. Claudiani Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma Cancer 76 1995 1662 1664
144. B. Brans, G. Laureys, V. Schelfhout Activity of iodine-123 metaiodobenzylguanidine in childhood neuroblastoma: Lack of relation to tumour differentiation in vivo Eur J Nucl Med 25 1998 144 149
145. H.M. van Santen, J. de Kraker, B.L. van Eck High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma Cancer 94 2002 2081 2089
146. A. Quach, L. Ji, V. Mishra, A. Sznewajs Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma Pediatr Blood Cancer 56 2011 191 201
147. B. Weiss, A. Vora, J. Huberty Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma J Pediatr Hematol/Oncol 25 2003 543 547
148. A. Garaventa, C. Gambini, G. Villavecchia Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine Cancer 97 2003 1332 1338
149. A.A. Pathirana, S. Vinjamuri, C. Byrne (131)I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome Eur J Surg Oncol 27 2001 404 408
150. S.D. Safford, R.E. Coleman, J.P. Gockerman Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid Results in 98 patients Cancer 101 2004 1987 1993
151. Z. Gao, H.J. Biersack, S. Ezziddin The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy J Cancer Res Clin Oncol 130 2004 649 656